On August 2, 2023, Forte Biosciences, Inc. filed a preliminary proxy statement soliciting proxies and urged the shareholders to vote against a shareholder proposal, requesting that the Board of Directors of the Company take all steps necessary to terminate without delay the Preferred Stock Rights Agreement, dated as of July 12, 2022, as amended on June 26, 2023, submitted by Funicular Funds, LP at the Company?s annual shareholders meeting scheduled to be held on September 19, 2023.